C
CUE
Cue Biopharma Inc
37.05
-0.79-2.09%After Hours: 39.99 +2.94 +7.94%19:30 09/18 EDT
OPEN/PREV CLOSE22.92/23.14
TODAY RANGE22.27-23.10
VOL307
MARKET CAP163.52M
52 WEEK RANGE4.971-45.50
AVG VOL (3M)267.93K
% TURNOVER1.76%
TURNOVER0
P/E (TTM)-0.8339
% RANGE3.54%
EPS(TTM)-26.9925
P/E(FORWARD)-0.9000
P/B50.96
BVPS0.4417
DIVIDEND--
P/S2.639
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP147.66M
SHARES OUTSTANDING7.26M
NEXT EARNINGS11/10-11/16
FREE FLOAT6.56M
LOT SIZE1
EX-DATE04/24/2026
News
Press Releases
Financial Reports
Profile
Seeking Alpha·09/21 21:14
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
TipRanks·09/21 20:30
B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff
Benzinga·09/21 17:06
12 Health Care Stocks Moving In Monday's Intraday Session
Seeking Alpha·09/21 15:20
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
Benzinga·09/21 14:45
What's Going on With Cue Biopharma Stock on Monday?
TipRanks·09/21 12:29
Cue Biopharma reports positive Phase 2 CUE-221 data
Benzinga·09/21 12:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Seeking Alpha·09/21 11:00
At a glance: stocks gapping up premarket
Benzinga·09/21 09:01
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
TipRanks·09/20 14:15
Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint
Seeking Alpha·09/18 15:28
Cue Biopharma is a new Buy at B. Riley on valuation
Benzinga·09/18 11:53
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Same Industry
Name/Symbol
Change%
Price